Cargando…

Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes

The aim of the present study was to manufacture new orally disintegrating tablets containing nimodipine–hydroxypropyl-β-cyclodextrin and nimodipine–methyl-β-cyclodextrin inclusion complexes. For obtaining a better quality of the manufactured tablets, three methods of the preparation of inclusion com...

Descripción completa

Detalles Bibliográficos
Autores principales: Novac, Marian, Musuc, Adina Magdalena, Ozon, Emma Adriana, Sarbu, Iulian, Mitu, Mirela Adriana, Rusu, Adriana, Gheorghe, Daniela, Petrescu, Simona, Atkinson, Irina, Lupuliasa, Dumitru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955142/
https://www.ncbi.nlm.nih.gov/pubmed/35335371
http://dx.doi.org/10.3390/molecules27062012
_version_ 1784676265576366080
author Novac, Marian
Musuc, Adina Magdalena
Ozon, Emma Adriana
Sarbu, Iulian
Mitu, Mirela Adriana
Rusu, Adriana
Gheorghe, Daniela
Petrescu, Simona
Atkinson, Irina
Lupuliasa, Dumitru
author_facet Novac, Marian
Musuc, Adina Magdalena
Ozon, Emma Adriana
Sarbu, Iulian
Mitu, Mirela Adriana
Rusu, Adriana
Gheorghe, Daniela
Petrescu, Simona
Atkinson, Irina
Lupuliasa, Dumitru
author_sort Novac, Marian
collection PubMed
description The aim of the present study was to manufacture new orally disintegrating tablets containing nimodipine–hydroxypropyl-β-cyclodextrin and nimodipine–methyl-β-cyclodextrin inclusion complexes. For obtaining a better quality of the manufactured tablets, three methods of the preparation of inclusion complexes, in a 1:1 molar ratio, were used comparatively; namely, a solid-state kneading method and two liquid state coprecipitation and lyophilization techniques. The physical and chemical properties of the obtained inclusion complexes, as well as their physical mixtures, were investigated using Fourier transformed infrared spectroscopy, scanning electron microscopy, X-ray diffraction analyses, and differential scanning calorimetry. The results showed that the lyophilization method can be successfully used for a better complexation. Finally, the formulation and precompression studies for tablets for oral dispersion, containing Nim–HP-β-CD and Nim–Me-β-CD inclusion complexes, were successfully assessed.
format Online
Article
Text
id pubmed-8955142
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89551422022-03-26 Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes Novac, Marian Musuc, Adina Magdalena Ozon, Emma Adriana Sarbu, Iulian Mitu, Mirela Adriana Rusu, Adriana Gheorghe, Daniela Petrescu, Simona Atkinson, Irina Lupuliasa, Dumitru Molecules Article The aim of the present study was to manufacture new orally disintegrating tablets containing nimodipine–hydroxypropyl-β-cyclodextrin and nimodipine–methyl-β-cyclodextrin inclusion complexes. For obtaining a better quality of the manufactured tablets, three methods of the preparation of inclusion complexes, in a 1:1 molar ratio, were used comparatively; namely, a solid-state kneading method and two liquid state coprecipitation and lyophilization techniques. The physical and chemical properties of the obtained inclusion complexes, as well as their physical mixtures, were investigated using Fourier transformed infrared spectroscopy, scanning electron microscopy, X-ray diffraction analyses, and differential scanning calorimetry. The results showed that the lyophilization method can be successfully used for a better complexation. Finally, the formulation and precompression studies for tablets for oral dispersion, containing Nim–HP-β-CD and Nim–Me-β-CD inclusion complexes, were successfully assessed. MDPI 2022-03-21 /pmc/articles/PMC8955142/ /pubmed/35335371 http://dx.doi.org/10.3390/molecules27062012 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Novac, Marian
Musuc, Adina Magdalena
Ozon, Emma Adriana
Sarbu, Iulian
Mitu, Mirela Adriana
Rusu, Adriana
Gheorghe, Daniela
Petrescu, Simona
Atkinson, Irina
Lupuliasa, Dumitru
Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes
title Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes
title_full Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes
title_fullStr Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes
title_full_unstemmed Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes
title_short Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes
title_sort manufacturing and assessing the new orally disintegrating tablets, containing nimodipine-hydroxypropyl-β-cyclodextrin and nimodipine-methyl-β-cyclodextrin inclusion complexes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955142/
https://www.ncbi.nlm.nih.gov/pubmed/35335371
http://dx.doi.org/10.3390/molecules27062012
work_keys_str_mv AT novacmarian manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT musucadinamagdalena manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT ozonemmaadriana manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT sarbuiulian manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT mitumirelaadriana manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT rusuadriana manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT gheorghedaniela manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT petrescusimona manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT atkinsonirina manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes
AT lupuliasadumitru manufacturingandassessingtheneworallydisintegratingtabletscontainingnimodipinehydroxypropylbcyclodextrinandnimodipinemethylbcyclodextrininclusioncomplexes